The DNA printing technology received backing from investors including Merck Group, Illumina, Danaher and Agilent to hike its total funding to $280m.

Eli Lilly, MRL Ventures Fund and Leaps by Bayer were among the participants in a round disclosed as the gastrointestinal disorder drug developer launched.

The TigerMed-backed clinical research provider reportedly secured near to $100m in a round co-led by Sequoia Capital China and GL Ventures.

The cancer therapeutics developer has followed up an Eli Lilly-backed first close with an extra $25m, taking the round to $82.6m.

Novartis Venture Fund and Hikma Ventures are set to exit the online medical treatment provider in a cash-and-stock purchase by 23andme.

The digital therapeutics developer closed a series B round that included corporate venturing units and existing investors Hikma Ventures and Sanofi Ventures.

Takeda Ventures was among the participants in a $46.5m round closed nearly a year after its parent company launched a partnership with the immunotherapy developer.

Online insurance provider Justos raised $35.8m in a SoftBank-led series A round while social game studio GreenPark Sports closed a $31m series B that included Alameda Research.

Takeda, Merck & Co, Ipsen and Merck Group all scored exits as the immuno-oncology drug developer floated at the bottom of its IPO range.

Blue Venture Fund and CVS Health Ventures helped the telemedicine system developer raise funding which will boost its expansion into new markets and expand its treatment offering.